A detailed history of Legal & General Group PLC transactions in 89bio, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 80,748 shares of ETNB stock, worth $640,331. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,748
Previous 80,748 -0.0%
Holding current value
$640,331
Previous $597,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $3,989 - $5,235
542 Added 0.68%
80,748 $597,000
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $27,295 - $40,700
3,734 Added 4.88%
80,206 $642,000
Q1 2024

May 14, 2024

BUY
$8.13 - $13.77 $23,601 - $39,974
2,903 Added 3.95%
76,472 $890,000
Q4 2023

Feb 15, 2024

BUY
$6.66 - $16.03 $152,800 - $367,776
22,943 Added 45.32%
73,569 $821,000
Q3 2023

Nov 14, 2023

SELL
$15.06 - $19.41 $7,153 - $9,219
-475 Reduced 0.93%
50,626 $781,000
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $723,079 - $1.13 Million
51,101 New
51,101 $968,000
Q2 2022

Aug 22, 2022

SELL
$2.09 - $4.02 $1,713 - $3,296
-820 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$17.42 - $28.0 $1,742 - $2,800
-100 Reduced 10.87%
820 $15,000
Q1 2021

May 17, 2021

SELL
$20.22 - $26.73 $667 - $882
-33 Reduced 3.46%
920 $22,000
Q4 2020

Feb 12, 2021

BUY
$23.16 - $28.08 $4,238 - $5,138
183 Added 23.77%
953 $23,000
Q3 2020

Nov 13, 2020

BUY
$24.34 - $38.82 $8,713 - $13,897
358 Added 86.89%
770 $20,000
Q2 2020

Aug 14, 2020

BUY
$19.93 - $31.2 $79 - $124
4 Added 0.98%
412 $8,000
Q1 2020

May 14, 2020

SELL
$16.4 - $41.77 $3,165 - $8,061
-193 Reduced 32.11%
408 $10,000
Q4 2019

Feb 13, 2020

BUY
$19.75 - $33.44 $11,869 - $20,097
601 New
601 $16,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $369M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.